Gene therapy for ventricular tachyarrhythmias
1Heart and Vascular Research Center, MetroHealth Campus, Case Western Reserve University School of Medicine, 2500 MetroHealth Drive, Cleveland, OH 44109, USA. kdonahue@metrohealth.org
Gene Therapy
|April 27, 2012
Summary
Gene therapy offers a promising alternative for treating ventricular tachyarrhythmias, a primary cause of cardiac arrest. This review explores gene therapy
Area of Science:
- Cardiology
- Molecular Medicine
- Genetics
Background:
- Cardiac arrest is a leading cause of death globally.
- Ventricular tachyarrhythmias, often linked to structural heart disease, are the main cause of cardiac arrest.
- Current drug and device therapies for these arrhythmias have significant limitations.
Purpose of the Study:
- To review the fundamental mechanisms underlying ventricular arrhythmias.
- To summarize existing research on the application of gene therapy for ventricular tachyarrhythmias.
- To present gene therapy as a potential alternative to conventional treatments.
Main Methods:
- Literature review of basic mechanisms of ventricular arrhythmias.
- Synthesis of studies investigating gene therapy for ventricular tachyarrhythmias.
Main Results:
- Gene therapy is being explored as a novel therapeutic strategy.
- Understanding arrhythmia mechanisms is crucial for developing effective gene therapies.
Conclusions:
- Gene therapy holds potential as an alternative treatment for ventricular tachyarrhythmias.
- Further research is needed to fully establish gene therapy's role in managing cardiac arrest due to arrhythmias.
Related Concept Videos
01:25ECG Interpretation of Arrhythmias II: Atrial, Junctional and Ventricular Arrhythmias
Arrhythmia is a condition characterized by an irregular heart rhythm, with ECG changes that differ based on its origin and nature. The types of arrhythmias discussed below include atrial, junctional, and ventricular arrhythmias.Atrial ArrhythmiasPremature Atrial Complexes (PACs): PACs are early atrial beats caused by stress, caffeine, alcohol, electrolyte imbalances, hypoxia, hyperthyroidism, or certain medications (e.g., bronchodilators and decongestants). The ECG shows early P waves with an...
01:25Dysrhythmias VI: Management of Dysrhythmias
Dysrhythmia management involves a multifaceted approach, incorporating pharmacological treatments, medical procedures, surgical interventions, lifestyle modifications, and patient education.Pharmacological ManagementAntiarrhythmic Drugs:Class I (Sodium Channel Blockers): This class includes quinidine and procainamide, which reduce the speed of impulse conduction in the heart, stabilize the cardiac membrane, and control arrhythmias. Quinidine and procainamide are Class IA agents that prolong the...
01:28Dysrhythmias II: Classification of Tachyarrhythmias
Tachyarrhythmias are a type of dysrhythmia where the heart rate exceeds 100 beats per minute. Here are some common types of tachyarrhythmias:Sinus TachycardiaSinus tachycardia originates from increased impulses from the sinus node, leading to an elevated heart rate. It is often triggered by stress, fever, or exercise.Patients may experience palpitations, a sensation of a racing heart, dizziness, and chest discomfort.Causes and Risk Factors: Common causes include physical exertion, emotional...
00:59Gene Therapy
Gene therapy is a technique where a gene is inserted into a person’s cells to prevent or treat a serious disease. The added gene may be a healthy version of the gene that is mutated in the patient, or it could be a different gene that inactivates or compensates for the patient’s disease-causing gene. For example, in patients with severe combined immunodeficiency (SCID) due to a mutation in the gene for the enzyme adenosine deaminase, a functioning version of the gene can be inserted. The...
00:59Gene Therapy
Gene therapy is a technique where a gene is inserted into a person’s cells to prevent or treat a serious disease. The added gene may be a healthy version of the gene that is mutated in the patient, or it could be a different gene that inactivates or compensates for the patient’s disease-causing gene. For example, in patients with severe combined immunodeficiency (SCID) due to a mutation in the gene for the enzyme adenosine deaminase, a functioning version of the gene can be inserted. The...
01:26Heart Failure Drugs: Inotropic Agents
Positive inotropic agents are commonly used as the first line of treatment for heart failure. One such agent is digoxin, derived from the genus Digitalis, which has been known for centuries but effectively utilized since 1785. However, these cardiac glycosides can have potentially toxic effects due to their mechanism of action, which involves inhibiting Na+/K+-ATPase and increasing contractility. Digoxin is absorbed orally and distributed in various tissues, including the CNS. It has a long...